Tvardi Therapeutics, Inc. TVRD
Nasdaq · XNAS · stock · Pharmaceutical Preparations
Chart by TradingView
1/9
Piotroski F — financial health
-10.66
Altman Z″ — distress risk · distress
—
Dividend payout · no dividend
Financials (annual, from 10-K)
| FY | Revenue | Net income | Gross profit | Free cash flow | Equity |
|---|---|---|---|---|---|
| 2025 | — | -$18.2M | — | — | $20.9M |
| 2024 | $7.1M | -$29.4M | — | -$19.4M | -$91.1M |
| 2023 | $21.0M | -$118.5M | — | -$94.5M | -$62.1M |
| 2022 | $41.9M | -$85.5M | — | -$78.8M | $158.8M |
| 2021 | $23.0M | -$88.4M | — | -$60.1M | $227.5M |
| 2020 | $135.1M | $8.4M | — | -$5.8M | $249.0M |
Why these scores methodology →
Piotroski F-score: 1/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: -10.66 (distress)
- Working capital / assets 0.639
- Retained earnings / assets -3.444
- EBIT / assets -0.834
- Equity / liabilities 1.882
Source: SEC EDGAR filings · CIK 0001346830 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.